Genistein targets Wnt5a to alleviate temporomandibular joint osteoarthritis by suppressing JNK/JUN-dependent MMP9 activation.
Temporomandibular joint osteoarthritis (TMJ-OA) is a progressive degenerative joint disease characterized by cartilage destruction, extracellular matrix (ECM) degradation, and chronic inflammation, yet effective disease-modifying therapeutic targets and pharmacological interventions remain limited. Using a monosodium i...